Angelini Pharma breaks new ground
Published: June 21, 2022, 10: 58Updated: July 7, 2022, 10:33More than 100 years ago, the family business Angelini Pharma started as a small pharmaceutical laboratory. Today, the company has an international leading role in healthcare. The company is now breaking new ground and establishing itself in the Nordic region. Angelini Pharma has a long, solid history that stretches back to 1919. The company is a European leader in healthcare, where the areas of expertise are “Brain health” (central nervous system (CNS), mental health, including pain), rare diseases and self-care. The company is now being taken to the Nordic market to improve the quality of life for individuals suffering from serious illnesses. – For us, it is important that the patient is at the center and that we create the right conditions for a richer life. This is reflected in our corporate culture, says Fräs Anna Andersson, General Manager at Angelini Pharma Nordics. Unique corporate cultureAs a family-owned Italian company, Angelini Pharma tries to look after the whole for patients and relatives and offer support in addition to medicines. The corporate culture at Angelini Pharma is based in particular on the care, both of employees and those affected by diseases, but also of relatives. Common to all employees is that they are driven by a higher purpose and want to make a difference. – We have a holistic view of the healthcare sector where we believe that it is not only drug treatment that makes a difference, but several other factors also play a role, says Fräs Anna Andersson and aims, among other things, at new, pioneering ways to spread knowledge and support for individuals with epilepsy and their relatives. She believes that Angelini Pharma works actively to create gathering places where people can be stimulated to exchange thoughts, experiences and information. As an example, Angelini Pharma launched the ByMyEpilepSide campaign on International Epilepsy Day, 14 February, which aims to highlight – and combat – prejudice and the stigma of epilepsy. – Angelini Pharma is convinced that a combination of treatment and medicine, where also interaction and exchange of experience with other people affected by the same disease, are important components to reduce suffering, says Lars Nicklasson, Market Access and Public Affairs Director at Angelini Pharma Nordics .Collaboration drives healthcare forwardIn order to achieve the vision of increased well-being, cooperation between several societal actors is needed. Lars Nicklasson highlights the importance of taking advantage of and developing data from existing National Health Data Registers to better understand how patients and relatives are affected in real life. – As a completely new player in the Nordic region, we see a unique opportunity to really show our ambition to create a meaningful collaboration between industry, healthcare, patient organizations and decision-makers. We are convinced that joint efforts are a necessity to improve the situation for people affected, he says. About Angelini Pharma
Angelini Pharma is a leader in healthcare, with special strength and expertise in the areas of central nervous system (CNS) and mental health, including pain and rare diseases. The company is also a leading player in the self-care segment with very successful OTC brands worldwide. The company is directly active in 25 countries with more than 3,000 employees and commercializes its products in more than 70 countries through strategic alliances with leading international pharmaceutical groups.
Read more about Angelini Pharma here. The article is produced by Brand Studio in collaboration with Angelini Pharma and not an article by Dagens industri